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Synopsis .....................................
Identify persons with epilepsy by first looking for
prescriptions for particular antiseizure drugs. Fol-
low these prescriptions from the pharmacies to the
physicians who wrote them for patients. Ask the
physicians whether the patients have epilepsy. Fi-
nally, contact the patients who do have epilepsy to
elicit information about the impact ofthat condition
on their lives.
With these steps, it may be possible to carry out
successfully a probability survey of epilepsy in the
United States population. To learn more about this
approach, a field test was funded by the National
Institute of Neurological and Communicative Dis-
orders and Stroke (NINCDS) of the Public Health
Service. From 1978 through 1982, the work was
planned, carried out, and evaluated by Research
Triangle Institute, Research Triangle Park, NC.
Epilepsy is a sensitive topic to ask about in a
survey. Also, the condition is sufficiently rare to
render ordinary survey approaches inefficient. Even
if rarity were not an issue, there would be the prob-
lem of response error because a person with
epilepsy does not, as a rule, have much clinical
information on his or her condition. Better informa-
tion lies with the physician who provides the care,
but many physicians are busy with their practices.
Furthermore, their record systems are usually not
designed for easy retrieval of information, unless
the names ofpatients are available. In the survey
approach considered here, the names of patients
are obtained through a random sampling of pre-
scriptions for antiseizure drugs.
The field test was divided into three phases with
special activities reserved for each. The most im-
portant problem confronted was how to safeguard
the confidentiality of relationships between phar-
macist and patient and between physician and pa-
tient. Special guidelines on confidentiality were put
into effect for the data collection. These guidelines,
however, contributed to serious problems of non-
response-especiallyfor physicians. This article pro-
vides a brief account of the field test, including a
rationale for the survey strategy of finding cases
of epilepsy through prescriptions for antiseizure
drugs.
EPILEPSY REFERS TO A CATEGORY of chronic dis-
orders characterized by sudden, recurrent attacks
of brain dysfunction with abnormal electrical dis-
charges. These attacks, called seizures, are usually
associated with some alteration of consciousness
and may or may not involve convulsive movements.
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As a category, epilepsy embraces a wide variety of
manifestations, and it represents a major public
health problem in the United States. Measurement
of the scope of this problem is important, yet
difficult and expensive to achieve.
For many people with epilepsy, physicians pre-
scribe drugs to control or prevent seizures. The
choice of drugs depends partly upon the type of
seizures experienced. Another consideration is the
person's response to a given drug, namely, degree
of seizure control and seriousness of side effects. If
the response is unsatisfactory, another drug might
be substituted. There are, of course, victims of
epilepsy who do not take antiseizure drugs. Some of
these people have never been evaluated medically
for their problem. Others have not been treated in
several years or more, and their seizures no longer
recur.
In the United States, a survey of epilepsy in the
general population presents sizable difficulties. One
of these difficulties has to do with public attitudes
toward epilepsy. For centuries in the Western
world, epileptics were thought to be possessed by
demons (1,2). As recently as the turn of the cen-
tury, epileptics were considered morally corrupt
and mentally retarded (3). Negative stereotypes
persist today, prompting some sufferers of the dis-
order to hide their condition. Also, a physician may
occasionally choose to conceal a diagnosis of
epilepsy from a patient as a way to protect the
patient from social stigma. In this situation, the
patient would receive standard medical treatment,
though he or she would not know of the epilepsy.
Thus, to the extent that survey respondents decline
to reveal family members with epilepsy or are un-
aware that any family members have epilepsy (pos-
sibly because of actions taken by the family physi-
cian), a household survey of epilepsy will produce
undercounts.
A second difficulty in conducting a survey of
epilepsy is that this category of disorders affects
relatively few Americans-perhaps about 1 percent
(maybe less) of the general population. From the
public health standpoint, 1 percent is a large figure.
In the realm of neurology, 1 percent is an excep-
tionally large figure. In planning a survey, however,
1 percent is considered small. A standard, door-to-
door survey of households, with face-to-face inter-
views, would be impractical on the national level. A
telephone survey of households might be a more
cost-effective way to proceed. But there is still con-
siderable inefficiency when the characteristic of
interest has a 1 percent frequency. Furthermore,
the telephone offers no solution to the potential
problem of concealment of cases of epilepsy.
An alternative to the household survey is to find
victims of epilepsy through the health care system.
A survey of hospitals will not suffice, since hos-
pitalization is seldom required for treatment of
epilepsy. A survey ofthe physicians might be fruitful.
There are serious drawbacks, however, with this
approach. Physicians are often asked to participate
in surveys of one kind or another, so they might be
reluctant to cooperate in a survey of epilepsy, im-
portant as it may be. Even if physicians are willing
to cooperate, they might be unable to identify readi-
ly epilepsy cases among patients they have evalu-
ated or treated during a specified time period, be-
cause physicians typically organize their records
alphabetically by last name of patient. Also, those
physicians who consult away from their offices
might not have access to all of the patient records
on which they have written their clinical observa-
tions. Finally, some physicians in office practices
keep abbreviated records that are difficult for other
people to interpret. In this situation, physicians
cannot prudently delegate to supporting staff the
burden of survey response.
These considerations have led to a survey ap-
proach that places a minimal, though crucial, bur-
den upon physicians. The approach has three steps.
First, screen prescriptions at pharmacies, searching
for those prescriptions written for particular an-
tiseizure drugs. Second, contact physicians who
wrote the prescriptions of interest (from step 1), and
inquire about diagnoses of the patients whose
names appeared on those prescriptions. Third, con-
tact patients whom the physicians indicated had
epilepsy (from step 2), and inquire about drugs used
and where purchased. Also inquire about the social
and economic costs of having epilepsy.
This three-step approach was conceived as a
broad framework from which a national probability
survey of epilepsy could be designed. Avoided is
the risk of losing people who would deny their con-
dition. We of course restrict our attention to per-
sons who have within a specified time period had
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prescriptions filled for particular antiseizure drugs.
Aspects of this three-step approach have been
field-tested, and comprehensive reports of that in-
vestigation are available elsewhere (4,5,6). In this
article, we concentrate on the highlights of the field
test, giving special attention to the important issues
of confidentiality, survey response, and multiplic-
ity-that is, the problem of unknowingly count-
ing the same person more than once.
Methodology
Background. On the national level, the scope of the
epilepsy problem has been determined largely by
guesswork. For example, the existing information
on prevalence comes chiefly from community stud-
ies (7), and national estimates are presumed to be
more or less the same as those for the communities
surveyed. National estimates produced in this way
are, as Deming once observed, "worth no more
than the reputation of the man that signs the report"
(8). Although expert opinion may be useful, a sur-
vey should be planned scientifically to yield national
estimates that have margins of uncertainty based
upon probability theory, not opinion.
The field test described here was not intended to
produce national estimates. Rather, this test was an
investigation of methodology that could be useful in
a national survey of epilepsy. The survey would
have strictly enumerative aims: it would yield in-
formation about the scope of the epilepsy problem
in the noninstitutionalized population of the United
States; estimates from the survey would relate to
the frequency and the social and economic costs of
epilepsy to society; and techniques of probability
sampling would be used to select epilepsy sufferers
for the survey.
Many people with the disorder in the United
States benefit from membership in nonprofit organi-
zations that specialize in providing information and
other assistance to people with eilepsy. Taken to-
gether, the membership lists of these organizations
would not, however, provide a suitable master list
or frame from which to select victims for a national
probability survey. The master list would exclude a
large number of the people with epilepsy, and those
missing from the list would very likely be different
in important characteristics from those who are on
the list.
Since there is no complete roster of epilepsy vic-
tims in the United States, some alternate way is
needed to reach them with each individual of inter-
est having a determinable, nonzero probability of
selection. As mentioned previously, we considered
using prescriptions for antiseizure drugs. This ap-
proach to epilepsy, which also requires the partici-
pation of physicians, has many complications-
some legal, some operational. For this reason, a
field test was warranted.
Field test. Although community pharmacists have
generally had experience with marketing surveys
conducted on behalf of drug companies, they have
only been involved to a limited extent in health
studies. It was questionable whether pharmacists
would agree to perform a number of activities as
participants in a survey of epilepsy. The field test,
therefore, was divided into three phases. Phase I
was a small effort; its purpose was to obtain a pre-
liminary assessment of feasibility of the survey ap-
proach. Phase II was a period of time for the princi-
pal investigators to review the results of the first
phase and to decide whether to continue the proj-
ect. If the project was to be continued, the inves-
tigators would plan for the main effort, phase III. As
will become apparent, all three phases of the field
test were implemented.
Phase I. Our survey approach to epilepsy begins,
but does not end, with prescriptions for antiseizure
drugs. Since these drugs are often prescribed for
reasons other than controlling seizures, it is neces-
sary to contact the physicians who wrote the pre-
scriptions to find out whether the patients indeed
have epilepsy. Those patients who do have epilepsy
must be contacted about how the condition has
affected their lives. During each step, the privacy of
the patients must be vigorously maintained. Also,
the confidential relationships of pharmacist to pa-
tient and physician to patient must not be breached
through the actions of people connected with the
research. These constraints of privacy and confi-
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dentiality are not easily satisfied. What is legal may be
unethical. What is ethical may be offensive to the
public.
Early in the planning of phase I, we had to deter-
mine when and how the pharmacists, the physi-
cians, and the patients would be asked to become
involved in the investigation. Our main concern, of
course, was for the patients. To find a feasible way
to protect private information consistent with the
aims of the field test, we sought advice widely-
especially from lawyers and leaders of the phar-
maceutical and medical professions.
After careful consideration, we decided on the
following guidelines to maintain privacy and to pre-
serve confidentiality of the relationships among
pharmacists, physicians, and patients:
1. The pharmacist would establish initial contact
with the physician to determine his desire to partic-
ipate in the field test, and if the physician agreed to
participate, the pharmacist would transmit the
name(s) of the patient(s) to the physician.
2. If the physician declined to participate or was
not selected for contact, the data collector would
never remove the patient's name or the physician's
name from the pharmacy.
3. The physician or his office staff would establish
initial contact with selected patients; only after the
patient had agreed to be interviewed would inves-
tigators be privileged to receive the patient's name
or make any contact with the patient.
Although these guidelines complicated the survey
approach to epilepsy, they were considered neces-
sary, since it was impractical to obtain prior con-
sents of patients for review of prescriptions and
interview of physicians.
Phase I of the field test did include some data
collection. Nine pharmacies were selected by judg-
ment to represent a variety of situations, including
type of pharmacy, level of urbanization, region of
the country, and retail volume. One of the phar-
macies was a mail order business. Endorsements of
the research were obtained from medical and
pharmaceutical societies. A panel of experts pro-
duced a list of antiseizure drugs for use in the re-
search. Pharmacies were enlisted in the field test by
consultants in pharmacy administration. These con-
sultants also identified students in schools of phar-
macy who would serve as data collectors. Prescrip-
tions for antiseizure drugs of interest, filled during
selected weeks of the years 1970 through 1977, were
identified and abstracted. Nine physicians were se-
lected by judgment to provide experience with sev-
eral specialties. Seven of the physicians, and prox-
ies for the other two, were interviewed by one of
us (BSHH) about patients identified from the
screening of prescriptions. Finally, nine patients re-
sponded to a questionnaire concerned with the per-
sonal impact of epilepsy.
Phase ll. The limited experience of phase I was
evaluated during phase II, a planned hiatus in the
collection of data. Had there been a fiasco with the
carefully nurtured field operations of phase I, the
research would have been quickly terminated as a
result of reviews undertaken during phase II. For-
tunately, phase I was successful, and the experi-
ence indicated that a larger test was needed. We
therefore continued the research.
Phase III. The chief objectives in the main effort
of the field test were to implement fully the confi-
dentiality guidelines developed in phase I and assess
their feasibility; to obtain estimates of response
rates for pharmacies, physicians, and patients; and
to evaluate the multiplicity problem that arose from
our survey approach. The multiplicity problem was
simply that of producing overestimates of various
characteristics, such as the number of people with
epilepsy, because individuals can have more than
one prescription for antiseizure drugs and can pur-
chase the drugs at more than one pharmacy.
The list of antiseizure drugs used in phase I was
reviewed and revised slightly for phase III. The
revised list included 17 drugs. These are presented
in table 1, in two groups. Group 1 includes antisei-
zure drugs considered to be the most important in
controlling seizures. Group 2 includes antiseizure
drugs considered to be mainly adjuncts to other
drug therapies.
In phase III, 48 pharmacies were selected to re-
flect different conditions that might be expected in a
full-scale national survey. The pharmacies were lo-
cated in six places: Brooklyn, NY; Chapel Hill, NC;
Iowa City, IA; New Orleans, LA; Stockton, CA;
and Storrs, CT. Each of the sites was specially
defined to be the geographic area within 50 miles of
a preselected school of pharmacy. Large urban
areas were represented by Brooklyn and New Or-
leans. Smaller urban areas were represented by
Iowa City and Stockton. Rural areas were rep-
resented by Chapel Hill and Storrs. The pharmacies
were either community pharmacies or outpatient
clinic pharmacies, and eight were selected ran-
domly at each of the six sites.
The six schools of pharmacy, around which the
sites were defined, provided consultants in phar-
macy administration to assist with phase III. Each
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Table 1. Antiseizure drugs of interest during phase Ill of the
field test
Chemical name Principal use (seizure type)
Group 1
Carbamazepine. Generalized tonic-clonic, complex
partial, simple partial
Clonazepam .... Absence, myoclonic
Ethosuximide ... Absence
Phenobarbital .. Generalized tonic-clonic, complex
partial, simple partial
Phenytoin ...... Generalized tonic-clonic, complex
partial, simple partial
Primidone ...... Generalized tonic-clonic, complex
partial, simple partial




Ethotoin ........ Generalized tonic-clonic, complex
partial
Mephenytoin ... Refractory generalized tonic-clonic,
complex partial
Mephobarbital .. Generalized tonic-clonic, absence
Metharbital ..... Generalized tonic-clonic, absence,
myoclonic
Methsuximide .. Refractory absence
Paramethadione Refractory absence




consultant was called upon to identify two or three
pharmacy students who would collect data at the
pharmacies. The students had to have a working
knowledge of pharmacy filing systems and experi-
ence in reading prescriptions. The students working
in phase III, unlike those of phase I, also had to
interview physicians and patients.
The consultants in pharmacy administration were
responsible for contacting the pharmacies selected
for study, to explain the field test and seek the
participation of the stores. As an incentive to partic-
ipate, the consultants offered professional books
valued at up to $50. A cash incentive of $50 was
available to pharmacists as an alternative to the
books. Some chain pharmacies were not authorized
individually to decide whether or not they could
participate. In these situations, the consultants con-
tacted the chain management directly about the field
test.
There was a legal barrier to some pharmacy ac-
tivities of phase III. A California regulation prohib-
ited access to pharmacy prescription files by per-
sons not employed by the pharmacy. After consul-
tations with the California Board of Pharmacy and
the Office of the Attorney General, it was decided to
modify the procedures for data collection. In Cali-
fornia, the pharmacy students who screened the
prescriptions would actually be hired by the phar-
macies where the work was to be done. Each phar-
macy was reimbursed for the labor costs plus a 20
percent surcharge for overhead expenses.
Under the confidentiality guidelines, pharmacists
participating in the field test were personally to seek
the cooperation of selected physicians. Pharmacists
were also to transmit the names of patients to the
physicians. A modest reimbursement, separate
from the $50 incentive, was provided to pharmacists
for this effort.
To simplify the work of obtaining cooperation of
physicians, we took advantage of a fortunate cir-
cumstance. Each physician licensed to prescribe
drugs has a unique number from the Drug Enforce-
ment Administration. In phase III, the DEA number
of each physician selected was transmitted from the
participating pharmacies to the survey office.
There, the DEA numbers were listed by pharmacy.
When two or more pharmacies provided the same
DEA number, it was assigned to only one of those
pharmacies-the one with the smallest number of
identified physicians. Thus, pharmacists from dif-
ferent stores did not approach the same physician
about taking part in the field test. This avoided a
nuisance in the physician's office; it also offered an
opportunity to balance somewhat the burden of
pharmacists in contacting physicians for the study.
The physicians in phase III were interviewed by
pharmacy students about patients identified at the
pharmacies. To avoid ambiguities of terminology
for epilepsy categories, each physician was asked to
make use of a preliminary version of the Interna-
tional Classification of Epileptic Seizures when re-
sponding about patients. This classification, later
revised (9), was based upon clinical observation and
laboratory evidence.
Those patients identified were eligible for a brief
interview by telephone about their use of antisei-
zure drugs and the number of pharmacies where the
drugs were purchased. Patients were not asked, in
phase III, to respond to the detailed questionnaire
concerned with the social and economic costs of
having epilepsy. From the confidentiality guide-
lines, the physicians or supporting staff had respon-
sibility for approaching patients about participation
in the field test. There was no reimbursement for
this effort.
The interviews of patients were performed usu-
ally by supporting staff of the physicians and occa-
sionally by pharmacy students. The information ob-
tained was important in quantifying the severity of
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the multiplicity problem that would arise if our ap-
proach through pharmacies was used in a probabil-
ity survey of epilepsy. To take account of this mul-
tiplicity problem, one of us (JTL) devised some
special statistical estimators (5,10).
Results
Although phase III was the main investigation of
the field test, there were activities in phase I that
were not carried over to phase III. One of these was
an important comparison of prescription data col-
lected prospectively and retrospectively. The ques-
tion was this: Would pharmacists in the course of
their normal workday list prescriptions of particular
antiseizure drugs as they were being filled or re-
filled? To answer this question, pharmacists in six
stores were asked to list the prescriptions of interest
prospectively over a 2-week period. Then, after the
fact, pharmacy students came into the stores and
reviewed all prescription files for the same 2-week
period. The students, with their concentrated effort,
were better able to identify the prescriptions of
interest: 138 prescriptions for the students versus
112 prescriptions for the pharmacists. From this
comparison and similar work at a hospital phar-
macy, we embraced the idea of retrospective iden-
tification of prescriptions.
In phase III, getting the selected pharmacies to
participate in the research proved difficult, even
with the $50 cash incentive that was offered. This
experience is summarized in table 2. Of the 48
pharmacies selected, only 27 agreed to participate
after the initial contacts were made by the consul-
tants in pharmacy administration. Because this
level of cooperation was unacceptable, the consul-
tants returned to the nonparticipating pharmacies to
invite them once again to join in the research. This
effort produced an additional 4 pharmacies. There
were, then, a total of 31 pharmacies out of 48 that
had agreed to participate. In survey terms, the re-
sponse rate was 64.6 percent; which was still unac-
ceptably low.
After a review of developments, we made two
adjustments in the procedures for approaching
pharmacies. Financial incentives were increased to
further encourage the nonparticipating pharmacies
to join the study. Instead of $50, the incentives were
$200 to $300 for nonchain pharmacies and $300 to
$500 for chain pharmacies. Also, survey specialists,
rather than the consultants, would contact the
pharmacies. In the original sample of 48 phar-
macies, use of the adjusted procedures produced an
additional 8 pharmacies beyond the 31 that had al-
Table 2. Pharmacy participation in phase l1l, by site
Category CA CT IA LA NC NY Total NY'
Initial contact ...... 4 5 6 5
1st conversion ..... ... ... ... 1







Total .............. 7 6 8 7 7 4 39 10
Sample size ....... 8 8 8 8 8 8 48 12
I Special substudy confined strictly to the Borough of Brooklyn. Experts in
survey operations, who were knowledgeable in methods of gaining cooperation,
approached pharmacies about participation. In the original sample of 48 phar-
macies, participation was first solicited by faculty members of local schools of
pharmacy.
ready agreed to participate (table 2), thereby boost-
ing the response rate to 81.3 percent.
To evaluate further the procedures for approach-
ing pharmacies, a special substudy was undertaken
in the Borough of Brooklyn, New York City. (See
NY' in table 2.) A fresh sample of 12 pharmacies
was selected. These pharmacies were initially ap-
proached by survey specialists experienced in field
operations. The original $50 incentive was offered,
and 7 of the 12 pharmacies agreed to participate in
the research. This compared with 2 of 8 Brooklyn
pharmacies from the earlier work. For return visits
to the nonparticipating pharmacies, the higher in-
centives mentioned previously were offered. Fi-
nally, 10 of the 12 pharmacies in the substudy
agreed to cooperate in the research, a response rate
of 83.3 percent. We considered the Brooklyn sub-
study to be a severe test of the new procedures.
Higher response rates would be expected in most
other localities.
In the original sample of 48 pharmacies, the non-
cooperating pharmacies were replaced by other
pharmacies willing to join in the research. In each of
the 48 participating pharmacies, some 2,000 pre-
scriptions were selected randomly. Generally,
about 880 prescriptions were selected for the study
year 1980, and 280 prescriptions were selected for
each of the years 1976, 1977, 1978, and 1979. For
1980 alone, 40,818 prescriptions were screened and
273 prescriptions for antiseizure drugs of interest
were identified. The screening ratio was 0.7 per-
cent.
Data collection for physicians and patients was
carried out at all sites except New Orleans. There,
following the pharmacy work, field operations were
suspended because delays caused all of the students
to leave the project. By that time, the students had
graduated from school and wanted to pursue their
careers. At the remaining five sites, 168 physicians
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were identified as having written prescriptions for
the particular antiseizure drugs of interest. Of these
physicians, 71 agreed to cooperate, 34 refused to
cooperate, and 63 could not cooperate. The latter
group included physicians in all types of situations;
for example, several physicians were away on vaca-
tion and did not return until after the scheduled
completion of data collection. Interviews were
completed with only 62 of the 71 cooperating physi-
cians. These interviews were in regard to 71 pa-
tients, 44 of whom were said to have epilepsy. The
physicians allowed contact with 33 patients; only 20
were interviewed. The remaining 9 physicians and
13 patients were not interviewed, for reasons of
time and cost.
Information on use and purchase of antiseizure
drugs was obtained from the patients: they reported
an average of 1.95 antiseizure drugs used. Ten of
the 20 patients reported using only one antiseizure
drug. By contrast, the physicians also reported on
the number of antiseizure drugs used by the pa-
tients. That number was 1.6 drugs, on average.
There was exact agreement between physician and
patient in 14 instances. On the number of phar-
macies where antiseizure drugs were purchased, the
patients reported an average of 1.3 pharmacies. Six-
teen of 20 patients purchased antiseizure drugs at
just one pharmacy.
Discussion
The confidentiality guidelines were central to the
field test. The protocol for data collection was con-
structed around them, and the results of the field
test were subsequently affected by them. The guide-
lines were developed for the field test, and by and
large they were followed. The major difficulty was
that pharmacists were reluctant to call physicians
and ask them to participate in the study. Several
pharmacists refused to do it; they requested that the
pharmacy student call the physicians about joining
the study. On those occasions, the pharmacy stu-
dents did telephone the physicians. They always
indicated, however, that they were calling for the
pharmacy. A similar situation obtained when physi-
cians refused to participate in the study. Since it
was too much to ask the pharmacists to call the
refusing physicians a second time, survey spe-
cialists were brought in for this purpose. They,
too, called as representatives of the pharmacy.
Nonresponse was a serious problem at the phar-
macy level, at the physician level, and at the patient
level. This was disturbing because nonresponse can
dramatically affect survey estimates. The proce-
dures used in the Brooklyn substudy may be the
solution to the nonresponse problem for phar-
macies. As for physicians and patients, their non-
response problems resulted partly from artificial
circumstances. For example, data collection from
them had to be scaled back because resources were
diverted to the Brooklyn substudy of pharmacy par-
ticipation. Nonresponse for physicians might be re-
duced by offering financial incentives, as was done
for the pharmacists. It might also be helpful to mod-
ify the confidentiality guidelines so that survey
specialists would be responsible for making the con-
tacts from pharmacy to physician. These contacts
could be made in a way that would not violate
privileged relationships. Nonresponse of patients
resulted principally from the physicians' barring con-
tact. This could be the most important nonresponse
problem of the three, because the reasons for bar-
ring contact might well be related to study variables
of interest.
The multiplicity information is skimpy-yet
thought-provoking. Eighty percent of the patients
purchased their antiseizure drugs at only one phar-
macy. On average, all of them purchased their drugs
at essentially one pharmacy. If this finding would
hold beyond our sample size of 20, then it might be
possible to do a morbidity survey of epilepsy with-
out contacting patients at all. Not having to contact
patients would probably result in a greater response
by physicians to the survey. We assume that infor-
mation obtained from physicians on number of an-
tiseizure drugs used by patients would be accept-
able. Again, in 14 of 20 instances, we had complete
agreement between physician and patient on num-
ber of drugs used by the patient.
Overall, the experience of the field test suggests
that the pharmacy-physician-patient approach to
finding people with epilepsy could perhaps be the
basis for a probability survey of epilepsy in the
United States. More testing is needed, however,
under conditions that would apply in an actual sur-
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vey. A successful application of the approach re-
quires high rates of participation for pharmacies,
physicians, and patients. A survey of epilepsy
would best be restricted to noninstitutionalized
populations. Even at that, the resulting estimates
would exclude those who had never been treated for
their epilepsy. The estimates would also exclude
persons with epilepsy who, during the specified
time period, had not had a prescription filled for any
antiseizure drug of interest. These limitations not-
withstanding, the survey could, if successfully im-
plemented, provide morbidity and cost data useful
for administrative purposes, such as planning for
public services. An added benefit of the survey
could be data on distributions of antiseizure drugs
prescribed.
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Synopsis .....................................
The University of California at Los Angeles
School of Public Health, in collaboration with the
Los Angeles County Department of Health Ser-
vices, compiled data and developed a standardized
format that displayed a comparison of mortality
and morbidity data between Los Angeles County,
the State of California, and the United States in
1960, 1970, and 1980for 16 health topic areas. Find-
ings noted both favorable and unfavorable health
trends, as well as substantial data collection prob-
lems.
In 1980, compared with the United States, the
Los Angeles County rates for tuberculosis, gonor-
rhea, syphilis, and hepatitis B were as much as
45 to 128 percent higher, the homicide rate was
more than double, and, for the population aged 65
years and over, the cirrhosis of the liver rate was
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